




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

0300
Sequence

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/972,035	10/04/2001	Daniel Albert Wettstein	1907.03

26698
MYRIAD GENETICS INC.
LEGAL DEPARTMENT
320 WAKARA WAY
SALT LAKE CITY, UT 84108



CONFIRMATION NO. 2866

FORMALITIES LETTER



OC000000007327253

Date Mailed: 01/17/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent Application of WETTSTEIN *et al.*

Serial No.: US 09/972,035

Filed: October 4, 2001

Title: Tsg101-GAG6p INTERACTION AND USE THEREOF

#8

Group Art Unit: 1653

April 3, 2002

Box Missing Parts

Commissioner for Patents

Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:


Transmitted herewith is a copy of a "Sequence Listing" in paper form for the above-identified patent application as required by 37 C.F.R. § 1.821(c), and a copy of the "Sequence Listing" in computer readable form as required by 37 C.F.R. § 1.821(e).

As required by 37 C.F.R. § 1.821(f), I hereby state that the sequence listing information recorded in computer readable form is identical to the written sequence listing. Further, as required by 37 C.F.R. § 1.821(g), I hereby state that no new matter is introduced by the submission of both forms of the sequence listing.

A petition for a one-month extension of time is being filed concurrently with this response. It is believed that no other fees are due, nor extensions required, in connection with this response. However, if the Commissioner finds such a fee is due or extension required, please charge our Deposit Account No. 50-1627.

Respectfully submitted,

By:



Jay Z. Zhang

Registration No. 44,003

Myriad Genetics, Inc.

320 Wakara Way

Salt Lake City, UT 84108


(801) 584-3600

Customer Number: 26698

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

Date of Deposit: April 3, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to The Honorable Commissioner of Patents and Trademarks, Washington, D.C. 20231


 Michael Moreno

4-3-02
 Date



#7
ENTERED OIPE

RAW SEQUENCE LISTING

DATE: 04/12/2002

PATENT APPLICATION: US/09/972,035

TIME: 14:36:02

Input Set : A:\1907.03 2002-03-25 SEQLIST HLL.ST25.txt

Output Set: N:\CRF3\04122002\I972035.raw

3 <110> APPLICANT: Myriad Genetics, Inc.
4 Wettstein, Daniel A
5 Morham, Scott
6 Zavitz, Kenton
8 <120> TITLE OF INVENTION: Tsg101-GAGp6 INTERACTION AND USE THEREOF
10 <130> FILE REFERENCE: 1907.03
12 <140> CURRENT APPLICATION NUMBER: US 09/972,035
13 <141> CURRENT FILING DATE: 2001-10-04
15 <150> PRIOR APPLICATION NUMBER: US 60/276,259
16 <151> PRIOR FILING DATE: 2001-03-14
18 <160> NUMBER OF SEQ ID NOS: 32
20 <170> SOFTWARE: PatentIn version 3.1
22 <210> SEQ ID NO: 1
23 <211> LENGTH: 4
24 <212> TYPE: PRT
25 <213> ORGANISM: Human immunodeficiency virus
27 <400> SEQUENCE: 1
29 Pro Thr Ala Pro
30 1
33 <210> SEQ ID NO: 2
34 <211> LENGTH: 4
35 <212> TYPE: PRT
36 <213> ORGANISM: Mutant human immunodeficiency virus
38 <400> SEQUENCE: 2
40 Pro Thr Thr Pro
41 1
44 <210> SEQ ID NO: 3
45 <211> LENGTH: 4
46 <212> TYPE: PRT
47 <213> ORGANISM: Human immunodeficiency virus
49 <400> SEQUENCE: 3
51 Pro Ser Ala Pro
52 1
55 <210> SEQ ID NO: 4
56 <211> LENGTH: 4
57 <212> TYPE: PRT
58 <213> ORGANISM: Mutant human immunodeficiency virus
60 <400> SEQUENCE: 4
62 Pro Ser Thr Pro
63 1
66 <210> SEQ ID NO: 5
67 <211> LENGTH: 4
68 <212> TYPE: PRT

RAW SEQUENCE LISTING

DATE: 04/12/2002

PATENT APPLICATION: US/09/972,035

TIME: 14:36:02

Input Set : A:\1907.03 2002-03-25 SEQLIST HLL.ST25.txt

Output Set: N:\CRF3\04122002\I972035.raw

69 <213> ORGANISM: Mutant human immunodeficiency virus
71 <400> SEQUENCE: 5
73 Pro Ile Ala Pro
74 1
77 <210> SEQ ID NO: 6
78 <211> LENGTH: 4
79 <212> TYPE: PRT
80 <213> ORGANISM: Mutant human immunodeficiency virus
82 <400> SEQUENCE: 6
84 Pro Ile Thr Pro
85 1
88 <210> SEQ ID NO: 7
89 <211> LENGTH: 5
90 <212> TYPE: PRT
91 <213> ORGANISM: Human immunodeficiency virus
93 <400> SEQUENCE: 7
95 Glu Pro Thr Ala Pro
96 1 5
99 <210> SEQ ID NO: 8
100 <211> LENGTH: 5
101 <212> TYPE: PRT
102 <213> ORGANISM: Human immunodeficiency virus
104 <400> SEQUENCE: 8
106 Glu Pro Ser Ala Pro
107 1 5
110 <210> SEQ ID NO: 9
111 <211> LENGTH: 5
112 <212> TYPE: PRT
113 <213> ORGANISM: Human immunodeficiency virus
115 <400> SEQUENCE: 9
117 Pro Thr Ala Pro Pro
118 1 5
121 <210> SEQ ID NO: 10
122 <211> LENGTH: 5
123 <212> TYPE: PRT
124 <213> ORGANISM: Human immunodeficiency virus
126 <400> SEQUENCE: 10
128 Pro Ser Ala Pro Pro
129 1 5
132 <210> SEQ ID NO: 11
133 <211> LENGTH: 6
134 <212> TYPE: PRT
135 <213> ORGANISM: Human immunodeficiency virus
137 <400> SEQUENCE: 11
139 Glu Pro Thr Ala Pro Pro
140 1 5
143 <210> SEQ ID NO: 12
144 <211> LENGTH: 6
145 <212> TYPE: PRT

RAW SEQUENCE LISTING

DATE: 04/12/2002

PATENT APPLICATION: US/09/972,035

TIME: 14:36:02

Input Set : A:\1907.03 2002-03-25 SEQLIST HLL.ST25.txt

Output Set: N:\CRF3\04122002\I972035.raw

146 <213> ORGANISM: Human immunodeficiency virus
148 <400> SEQUENCE: 12
150 Glu Pro Ser Ala Pro Pro
151 1 5
154 <210> SEQ ID NO: 13
155 <211> LENGTH: 6
156 <212> TYPE: PRT
157 <213> ORGANISM: Human immunodeficiency virus
159 <400> SEQUENCE: 13
161 Pro Glu Pro Thr Ala Pro
162 1 5
165 <210> SEQ ID NO: 14
166 <211> LENGTH: 6
167 <212> TYPE: PRT
168 <213> ORGANISM: Human immunodeficiency virus
170 <400> SEQUENCE: 14
172 Pro Glu Pro Ser Ala Pro
173 1 5
176 <210> SEQ ID NO: 15
177 <211> LENGTH: 7
178 <212> TYPE: PRT
179 <213> ORGANISM: Human immunodeficiency virus
181 <400> SEQUENCE: 15
183 Arg Pro Glu Pro Thr Ala Pro
184 1 5
187 <210> SEQ ID NO: 16
188 <211> LENGTH: 7
189 <212> TYPE: PRT
190 <213> ORGANISM: Human immunodeficiency virus
192 <400> SEQUENCE: 16
194 Arg Pro Glu Pro Ser Ala Pro
195 1 5
198 <210> SEQ ID NO: 17
199 <211> LENGTH: 7
200 <212> TYPE: PRT
201 <213> ORGANISM: Human immunodeficiency virus
203 <400> SEQUENCE: 17
205 Pro Glu Pro Thr Ala Pro Pro
206 1 5
209 <210> SEQ ID NO: 18
210 <211> LENGTH: 7
211 <212> TYPE: PRT
212 <213> ORGANISM: Human immunodeficiency virus
214 <400> SEQUENCE: 18
216 Pro Glu Pro Ser Ala Pro Pro
217 1 5
220 <210> SEQ ID NO: 19
221 <211> LENGTH: 8
222 <212> TYPE: PRT

RAW SEQUENCE LISTING

DATE: 04/12/2002

PATENT APPLICATION: US/09/972,035

TIME: 14:36:02

Input Set : A:\1907.03 2002-03-25 SEQLIST HLL.ST25.txt

Output Set: N:\CRF3\04122002\I972035.raw

223 <213> ORGANISM: Human immunodeficiency virus
225 <400> SEQUENCE: 19
227 Glu Pro Thr Ala Pro Pro Glu Glu
228 1 5
231 <210> SEQ ID NO: 20
232 <211> LENGTH: 8
233 <212> TYPE: PRT
234 <213> ORGANISM: Human immunodeficiency virus
236 <400> SEQUENCE: 20
238 Glu Pro Ser Ala Pro Pro Glu Glu
239 1 5
242 <210> SEQ ID NO: 21
243 <211> LENGTH: 8
244 <212> TYPE: PRT
245 <213> ORGANISM: Human immunodeficiency virus
247 <400> SEQUENCE: 21
249 Glu Pro Thr Ala Pro Pro Ala Glu
250 1 5
253 <210> SEQ ID NO: 22
254 <211> LENGTH: 9
255 <212> TYPE: PRT
256 <213> ORGANISM: Human immunodeficiency virus
258 <400> SEQUENCE: 22
260 Pro Glu Pro Thr Ala Pro Pro Glu Glu
261 1 5
264 <210> SEQ ID NO: 23
265 <211> LENGTH: 9
266 <212> TYPE: PRT
267 <213> ORGANISM: Human immunodeficiency virus
269 <400> SEQUENCE: 23
271 Pro Glu Pro Thr Ala Pro Pro Ala Glu
272 1 5
275 <210> SEQ ID NO: 24
276 <211> LENGTH: 9
277 <212> TYPE: PRT
278 <213> ORGANISM: Human immunodeficiency virus
280 <400> SEQUENCE: 24
282 Pro Glu Pro Ser Ala Pro Pro Glu Glu
283 1 5
286 <210> SEQ ID NO: 25
287 <211> LENGTH: 10
288 <212> TYPE: PRT
289 <213> ORGANISM: Human immunodeficiency virus
291 <400> SEQUENCE: 25
293 Arg Pro Glu Pro Thr Ala Pro Pro Glu Glu
294 1 5 10
297 <210> SEQ ID NO: 26
298 <211> LENGTH: 10
299 <212> TYPE: PRT

RAW SEQUENCE LISTING

DATE: 04/12/2002

PATENT APPLICATION: US/09/972,035

TIME: 14:36:02

Input Set : A:\1907.03 2002-03-25 SEQLIST HLL.ST25.txt

Output Set: N:\CRF3\04122002\I972035.raw

300 <213> ORGANISM: Human immunodeficiency virus
302 <400> SEQUENCE: 26
304 Arg Pro Glu Pro Ser Ala Pro Pro Glu Glu
305 1 5 10
308 <210> SEQ ID NO: 27
309 <211> LENGTH: 10
310 <212> TYPE: PRT
311 <213> ORGANISM: Human immunodeficiency virus
313 <400> SEQUENCE: 27
315 Arg Pro Glu Pro Thr Ala Pro Pro Ala Glu
316 1 5 10
319 <210> SEQ ID NO: 28
320 <211> LENGTH: 10
321 <212> TYPE: PRT
322 <213> ORGANISM: Human immunodeficiency virus
324 <400> SEQUENCE: 28
326 Arg Pro Glu Pro Ser Ala Pro Pro Ala Glu
327 1 5 10
330 <210> SEQ ID NO: 29
331 <211> LENGTH: 13
332 <212> TYPE: PRT
333 <213> ORGANISM: Human immunodeficiency virus
335 <400> SEQUENCE: 29
337 Leu Gln Ser Arg Pro Glu Pro Thr Ala Pro Pro Glu Glu
338 1 5 10
341 <210> SEQ ID NO: 30
342 <211> LENGTH: 13
343 <212> TYPE: PRT
344 <213> ORGANISM: Human immunodeficiency virus
346 <400> SEQUENCE: 30
348 Leu Gln Ser Arg Pro Glu Pro Ser Ala Pro Pro Glu Glu
349 1 5 10
352 <210> SEQ ID NO: 31
353 <211> LENGTH: 14
354 <212> TYPE: PRT
355 <213> ORGANISM: Human immunodeficiency virus
357 <400> SEQUENCE: 31
359 Leu Gln Ser Arg Pro Glu Pro Thr Ala Pro Pro Glu Glu Ser
360 1 5 10
363 <210> SEQ ID NO: 32
364 <211> LENGTH: 14
365 <212> TYPE: PRT
366 <213> ORGANISM: Human immunodeficiency virus
368 <400> SEQUENCE: 32
370 Leu Gln Ser Arg Pro Glu Pro Ser Ala Pro Pro Glu Glu Ser
371 1 5 10

VERIFICATION SUMMARY

DATE: 04/12/2002

PATENT APPLICATION: US/09/972,035

TIME: 14:36:04

Input Set : A:\1907.03 2002-03-25 SEQLIST HLL.ST25.txt

Output Set: N:\CRF3\04122002\I972035.raw